There is a "situation" with your abs!
Abs have always been the measure of how "in shape" someone is when evaluating your own or someone...
Sigma-tau HealthScience is the manufacturer of two key AminoCarnitine® ingredients, which have been accepted by the USP Ingredient Verification Program. These ingredients are ArginoCarn® (brand of Acetyl-L-Carnitine Arginate Dihydrochloride) and GlycoCarn® (brand of Glycine Propionyl-L-Carnitine Hydrochloride).
Dietary supplementation with the naturally occurring nutrient L-Carnitine has been extensively studied as an aid to improve fatty acid metabolism and aerobic exercise capacity, to provide antioxidant benefits, and to enhance blood flow to active tissues (e.g., skeletal muscle and heart). While multiple forms of carnitine have been studied and are currently available, Propionyl-L-Carnitine (PLC) has been shown to best support healthy heart and skeletal muscle function. A patented and safe USP dietary form of PLC has been developed which is molecularly bonded to glycine, one of the precursor amino acids to carnitine biosynthesis. This form is known as Glycine Propionyl-LCarnitine (GPLC) or GlycoCarn®, and is one of the AminoCarnitines® branded and marketed by Sigma-tau HealthScience.
Sometimes, a well-known and valued supplement can be transformed to provide significant new benefits. Such is the case with L-Carnitine. Propionyl-L-Carnitine is a form that until very recently was restricted to medical uses. Now it finally is available more generally as Glycine Propionyl-L-Carnitine or Glycocarn®, which is a patented compound. Many health food shoppers will be surprised by the difference found with this next generation of L-Carnitine. This is the L-Carnitine with a focus on muscular energy, exercise recovery and reduced fatigue.
Last month we chatted with Dr. Stephen Sinatra about new nutrients to keep the heart and arteries healthy, particularly a nutrient called Propionyl- L-Carnitine (PLC). This month, we will focus on metabolic cardiology and how adenosine triphosphate (ATP), and thus its precursors, the carnitines, CoQ-10 and D-ribose, is the bottom line in heart health. Anybody with any type of cardiovascular disease has a heart that is always leaking ATP. The body can’t make it back fast enough by de novo (from the beginning) synthesis! It takes too long and the ATP leakage is faster. It’s all about ATP and less about oxygen!
Carnitine exists in two isomeric forms: L-Carnitine and D-Carnitine. The latter has no physiological role other than acting as a competitive inhibitor of L-Carnitine, the only isomer biologically active and with a fundamental role in the utilization of lipid substrates by the cellular mitochondria. There are in the marketplace other sources of d- or dl-carnitine of highly improbable efficacy and, in the case of D-Carnitine, not allowed for food or feed use. Sigma-tau HealthScience does not now nor has it ever been a supplier of any forms of carnitine other than the pure L-Carnitine form. L, dl- and l-isomers can be distinguished optically by using refractometric techniques that determine the specific rotation and therefore the optical purity of the isomer. Sigma-tau HealthScience L-Carnitine meets or exceeds all USP as well as other existing codex requirements for optical purity and, of course, other codex parameters.
Approximately twenty years ago, it was discovered that a particular factor produced within endothelial tissue specifically relaxes the adjacent smooth muscle of blood vessels thereby allowing vasodilation and increased blood flow to various tissues including skeletal muscle. This factor was initially referred to as endothelium-derived relaxing factor but is now known as nitric oxide. While nitric oxide serves as an important signaling molecule involved in numerous physiological functions (such as improved glucose transport and antioxidant properties) the role of nitric oxide and control of skeletal blood flow is the primary issue generally addressed with various proposed nutritional supplements. The marketing of these products is generally based on the assumptions that increased blood flow to exercising muscles will enable 1) increased levels of work output, and/or 2) increased resistance to fatigue with submaximal levels of work, and/or 3) increased recovery following exercise training.
Sigma-tau HealthScience is a wholly-owned subsidiary of the pharmaceutical group Sigma-tau Industries SpA Italy.